Sedation for Terminally Ill Patients with Cancer with Uncontrollable Physical Distress
- 1 February 2005
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Palliative Medicine
- Vol. 8 (1), 20-25
- https://doi.org/10.1089/jpm.2005.8.20
Abstract
Background: Relief of distressful symptoms in terminally ill patients with cancer is of prime importance. Use of sedation to accomplish this has been the focus of recent medical studies in countries other than Japan. We investigated the influence on consciousness of sedative drugs in a Japanese hospice. Design and subjects: We defined sedation as medical procedure to decrease level of consciousness in order to relieve severe physical distress refractory to standard interventions. We excluded increases in doses of morphine or other analgesic drugs resulting in secondary somnolence from the present study. We reviewed medical records of patients receiving sedation among 124 consecutive patients admitted to our palliative care unit between January and December in 1999. Results: The 63 patients who received sedation (50.3%) died an average of 3.4 days after its initiation. Major symptoms requiring sedation were dyspnea, general malaise/restlessness, pain, agitation, and nausea/vomiting. The Palliative Performance Status (PPS) just before sedation was 20 or less in 83% of patients. Drugs administered for sedation were midazolam, haloperidol, scopolamine hydrobromide, and chlorpromazine. During the few days before death, sedated patients were significantly more drowsy and less responsive than that in those receiving non-sedative treatment. Conclusions: Our data suggest the effectiveness of sedation in relieving severe, refractory physical symptoms in terminally ill Japanese patients with cancer. Further investigation to confirm safety and effectiveness of sedation in this context is warranted.Keywords
This publication has 20 references indexed in Scilit:
- Impaired communication capacity and agitated delirium in the final week of terminally ill cancer patients: prevalence and identification of research focusJournal of Pain and Symptom Management, 2003
- Correlation of the Dose of Midazolam for Symptom Control with Administration Periods: The Possibility of ToleranceJournal of Pain and Symptom Management, 2003
- Sedative Use in the Last Week of Life and the Implications for End-of-Life Decision MakingArchives of Internal Medicine, 2003
- Palliative sedation therapy: a review of definitions and usageInternational Journal of Palliative Nursing, 2002
- Proposed definitions for terminal sedationThe Lancet, 2001
- Terminal sedation in palliative medicine – definition and review of the literatureSupportive Care in Cancer, 2001
- Communication Capacity Scale and Agitation Distress Scale to measure the severity of delirium in terminally ill cancer patients: a validation studyPalliative Medicine, 2001
- A comparison of the use of sedatives in a hospital support team and in a hospicePalliative Medicine, 1997
- Midazolam A Review of its Pharmacological Properties and Therapeutic UseDrugs, 1984
- Biopharmaceutics of rectal administration of drugs in man IX. Comparative biopharmaceutics of diazepam after single rectal, oral, intramuscular and intravenous administration in manInternational Journal of Pharmaceutics, 1980